

Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease

Kristen L. Jablonski* and Michel Chonchol

Address: Division of Renal Diseases and Hypertension, University of Colorado Denver Anschutz Medical Campus, 12700 E. 19th Avenue C281, Aurora, CO 80045, USA

* Corresponding author: Kristen L. Jablonski (kristen.nowak@ucdenver.edu)

F1000Prime Reports 2014, **6**:72 (doi:10.12703/P6-72)

All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/legalcode>), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The electronic version of this article is the complete one and can be found at: <http://f1000.com/prime/reports/m/6/72>

Abstract

The number of patients requiring chronic hemodialysis is rapidly growing worldwide. Hemodialysis both greatly reduces quality of life and is associated with extremely high mortality rates. Management of care of patients requiring chronic hemodialysis is complex, and randomized controlled trials aimed at reducing primary outcomes of cardiovascular disease events, mortality, or both in this population have largely been unsuccessful. Topics of major concern in the management of maintenance hemodialysis patients as related to these outcomes include the overall cardiovascular disease burden, blood pressure control, anemia, abnormalities in mineral metabolism, and inflammation. The focus of this review is a discussion of these topics on the basis of current recommendations from major organizations, expert opinion, and the available randomized controlled trials to date. These issues are further complicated by sometimes conflicting observational and randomized controlled trial data. Overall, treatment options for reducing these endpoints in maintenance hemodialysis patients are limited, and future randomized controlled trials are essential to continuing to advance care in this population, with the goal of ultimately improving hard outcomes. Such trials should consider new therapies to better target these factors, additional risk factors that have not been well tested to date, and therapies with new targets, including inflammation.

Introduction

The number of patients with end-stage renal disease (ESRD) is rapidly growing worldwide, and the most recent estimate (2011) is greater than 600,000 patients treated for ESRD in the US alone [1]. The cost associated with the care of patients requiring chronic dialysis is substantial, and the current annual estimate for the US exceeds \$49 billion [1]. Chronic hemodialysis both greatly reduces quality of life and is associated with extremely high mortality rates, which are up to seven times greater than in the general population [1].

Management of patients requiring hemodialysis is complex, and randomized controlled trials (RCTs) aimed at reducing cardiovascular events and mortality in this population have largely been unsuccessful [2–7].

This review will consider topics of major concern in the management of maintenance hemodialysis patients as related to these outcomes, focusing on the overall cardiovascular disease (CVD) burden, blood pressure control, anemia, abnormalities in mineral metabolism, and inflammation. The focus will be on current recommendations from organizations, including Kidney Disease: Improving Global Outcomes (KDIGO) and the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI), expert opinion, and the available RCTs to date. It is expected that upon completion of this review the reader should have an appreciation for (a) the complex issues related to the management of care in maintenance hemodialysis patients, (b) controversies in management, including conflicting evidence from epidemiological studies

compared with RCTs, and (c) the need for future RCTs to further advance patient care and ultimately reduce mortality in this population.

Cardiovascular disease burden

Adjusted (for age, race, and gender) all-cause mortality rates are 7- to 8-fold greater in patients requiring chronic hemodialysis compared with the general population, and approximately 40% of deaths in this population are attributable to cardiovascular causes [1,8]. Risk factors for CVD in maintenance hemodialysis patients include both traditional risk factors such as diabetes and hypertension as well as unique non-traditional risk factors, including inflammation, oxidative stress, anemia, vascular calcification, and fluid and electrolyte shifts [9-11]. Notably, the National Kidney Foundation considers patients with chronic kidney disease (CKD) to be in the highest risk group (i.e. a coronary artery disease risk equivalent) for subsequent cardiovascular events [12]. As much as 50% of deaths in maintenance hemodialysis patients are attributable to cardiovascular causes [13], influenced in part by the development of atherosclerosis and arteriosclerosis, left ventricular hypertrophy (LVH), and sudden cardiac death.

The incidence and severity of coronary artery disease increases with declining estimated glomerular filtration rate (eGFR) and is present in over half of all patients with ESRD [14,15]. Atherosclerotic lesions are also characterized by vascular calcification. Intimal calcification occurs focally and is associated with both inflammation and overall atherosclerotic plaque burden [16]. Medial calcification also occurs, resulting from elastic fiber mineralization and vascular smooth muscle cell phenotypic changes resulting in upregulation of osteogenic programs [17]. This type of calcification is the more common form in ESRD and is associated with arterial stiffness, reduced myocardial perfusion, LVH, and heart failure [18]. The presence and extent of vascular calcification independently predicts future CVD and mortality in patients with ESRD [19,20].

Another important risk factor is the development of LVH, which occurs in over half of patients with an eGFR of less than 30 mL/minute per 1.73 m² [21]. Major mechanisms contributing to LVH are pressure overload, often resulting from long-standing hypertension and increased arterial stiffness and volume overload [22]. In addition, CKD-specific factors, including renin angiotensin aldosterone system (RAAS) activation, oxidative stress, inflammation, and severe anemia, play a role [22,23]. Finally, sudden cardiac death, resulting primarily from ventricular arrhythmias, accounts for the majority of cardiovascular deaths in

patients with ESRD and this appears to be unrelated to the presence of coronary artery disease [1,24]. Contributing factors include electrolyte abnormalities, rapid electrolyte changes during hemodialysis, LVH, and sympathetic nervous system activation [24,25].

The major RCTs aimed at reducing CVD events or mortality in patients with ESRD are outlined in Table 1. Overall, these trials, which have included targeting anemia [2], altering hemodialysis dose and flux [3], lowering lipids [4,6,26], reducing homocysteine levels [5], and treating secondary hyperparathyroidism [7], have been largely unsuccessful in reducing primary outcomes of CVD events, mortality, or both. The exception is the Study of Heart and Renal Protection (SHARP), which demonstrated a 17% [rate ratio 0.83, 95% confidence interval (CI) 0.74 to 0.94] lower relative risk of first major atherosclerotic event in a combined population of patients with CKD (n = 6,247) and maintenance dialysis patients (n = 3,023) with a combined treatment of simvastatin plus ezetimibe [26]. There was no significant reduction in relative risk in the subgroup of dialysis patients alone; however, the study was not powered to assess CKD and dialysis subgroups separately.

Of note, in the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, there was a nominally significant reduction in risk in the primary composite endpoint (time to death, myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event) with cinacalcet treatment in patients with moderate-to-severe hyperparathyroidism receiving maintenance hemodialysis after adjustment for baseline characteristics [7]. However, in the unadjusted, intent-to-treat analysis, there was no reduction in primary composite endpoint (hazard ratio 0.93, 95% CI 0.82 to 1.02). Finally, also included in Table 1 is a recent trial (Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril, or HDPAL) comparing treatment with a beta-blocker (atenolol) with angiotensin-converting enzyme inhibitor (ACEI – lisinopril) to achieve home blood pressure control to less than 140/90 mm Hg [27]. Although the primary outcome of the study was change in left ventricular mass index rather than CVD events or mortality, the study is noteworthy because it was terminated early because of an increased incidence rate ratio of serious cardiovascular events (2.36, 95% CI 1.36 to 4.23) as well as an increased composite of myocardial infarction, stroke, congestive heart failure, and cardiovascular-related death (2.29, 95% CI 1.07 to 5.21) in the lisinopril group compared with the atenolol group. This study is discussed further in the following section.

Table 1. Major randomized controlled trials targeting a reduction in cardiovascular disease events, mortality, or both

Study	Population	Study design	Primary outcome	Average follow-up time	Major results
Normal Hematocrit Study [2]	N = 1233 maintenance HD patients with clinical evidence of congestive heart failure or ischemic heart disease	Epoetin alfa dosed to maintain Hct of 42% versus 30% (open-label)	Length of time to death or first non-fatal MI	14 months (median)	Although the difference in event-free survival between the two groups did not reach the pre-specified statistical stopping boundary, the study was halted early. Risk ratio for the high-Hct group versus low-Hct group 1.3 (95% CI 0.9-1.9)
HEMO [3]	N = 1846 maintenance HD patients undergoing treatment 3 times per week	2x2 factorial design with standard versus high dialysis dose and low-flux versus high-flux dialyzer	Death from any cause	2.8 years (mean)	No effect of dose or flux on primary outcome High- versus standard-dose relative risk 0.96 (95% CI 0.84-1.10) High- versus low-flux relative risk 0.92 (95% CI 0.81-1.05)
4D study [4]	N = 1255 type II diabetics receiving maintenance HD	Atorvastatin (20 mg/day) versus placebo	Composite of CV death, non-fatal MI, or stroke	4 years (median)	No reduction in 1° endpoint: relative risk 0.92 (95% CI 0.77-1.1) or total mortality Reduced 2° outcome of cardiac events combined: 0.82 (0.68-0.99), but increased risk of fatal stroke 2.03 (1.05-3.93)
HOST [5]	N = 2056 total; n = 751 ESRD (98% male)	Capsule with 40 mg folic acid, 100 mg B6, and 2 mg B12 versus placebo	All-cause mortality	3.2 years (median)	No reduction in all-cause mortality: hazard ratio 1.04 (95% CI 0.91-1.18) For ESRD subgroup: hazard ratio = 1.04 (95% CI 0.83-1.28)
AURORA [6]	N = 2776 maintenance HD patients (50-80 years)	Rosuvastatin (10 mg/day) versus placebo	CV death, non-fatal MI, or non-fatal stroke	3.8 years (median)	Statin had no effect on 1° outcomes: hazard ratio 0.96 (95% CI 0.84-1.11)
SHARP [26]	N = 9270 total; n = 3023 receiving maintenance dialysis; no CVD history; at least 40 years of age	Simvastatin (20 mg/day) + ezetimibe (10 mg/day) versus placebo	First major atherosclerotic event (non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure)	4.9 years (median)	17% lower risk of 1° outcome: rate ratio 0.83 (95% CI 0.74-0.94) No change in rate ratio in the subgroup of dialysis patients (0.90; 95% CI 0.75-1.08), despite change in non-dialysis subgroup (0.78; 95% CI 0.67-0.91); however, not powered to assess these groups separately No change in mortality (vascular or total), but not primary outcome → would have needed larger sample size to detect based on the rate of event occurrence
EVOLVE [7]	N = 3883 patients with moderate-to-severe hyperparathyroidism receiving maintenance HD	Cinacalcet (progressive dose escalation) versus placebo	Composite of time to death, MI, hospitalization for unstable angina, heart failure, or peripheral vascular event	21.2 months (active) and 17.5 months (placebo) (median)	In unadjusted, intent-to-treat analysis, no reduction in primary outcome with cinacalcet: hazard ratio 0.93 (95% CI 0.82-1.02) After adjustment for baseline characteristics, nominally significant reduction of 12% (hazard ratio 0.88; 95% CI 0.79-0.97) Power was lost because lower-than-anticipated event rate; higher dropout in active group
HDPAL [27]	N = 200 maintenance HD patients with LVH + hypertension	Beta-blocker (atenolol) versus ACE inhibitor (lisinopril) to achieve home blood pressure control to <140/90 mm Hg	Change in left ventricular mass index	12 months	Study terminated early because serious CV events (IRR 2.36, 95% CI 1.36-4.23), a composite of MI, stroke, congestive heart failure, and CV-related death (IRR 2.29, 95% CI 1.07-5.21) as well as all-cause hospitalizations (IRR 1.61, 95% CI 1.18-2.19) were all greater in the lisinopril versus atenolol group.

Abbreviations: ACE, angiotensin-converting enzyme; AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; CI, confidence interval; CV, cardiovascular; ESRD, end-stage renal disease; EVOLVE, Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events; Hct, hematocrit; HD, hemodialysis; HDPAL, Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril; HEMO, the Hemodialysis study; HOST, Homocysteine in Kidney and End Stage Renal Disease ; IRR, incidence rate ratio; LVH, left ventricular hypertrophy; MI, myocardial infarction; SHARP, Study of Heart and Renal Protection.

Blood pressure control

Blood pressure is often poorly controlled and hypertension is very common in maintenance hemodialysis patients, and both are important predictors of all-cause mortality [1,28]. Though recommending pharmacologic treatment to lower blood pressure to a goal of less than 140/90 mm Hg in patients with non-dialysis-dependent CKD, the recently released Eighth Joint National Committee (JNC 8) guidelines issue no specific recommendation for maintenance dialysis patients [29]. Similarly, the recent KDIGO Blood Pressure Work Group clinical practice guidelines do not make specific recommendations for patients with ESRD, citing a lack of available robust evidence to guide such a recommendation [30]. Instead, the text refers the reader to the 2005 clinical practice guideline from K/DOQI, which recommends that pre-hemodialysis blood pressure and post-hemodialysis blood pressure targets be less than 140/90 and less than 130/80 mm Hg, respectively [31].

There is a controversy surrounding ideal blood pressure in maintenance dialysis patients, as epidemiological data have demonstrated a reverse J- or U-shaped curve of risk of mortality with blood pressure [32,33]. This may be explained in part by confounding factors, such that blood pressure is lower in individuals with antecedent cardiac disease, poor overall health, or both [33]. In addition, the association between blood pressure and mortality may change over time in chronic hemodialysis patients [34]. Of note, this association has never been confirmed in an RCT. Chronic hemodialysis patients also exhibit great blood pressure variability, and this variability is a significant predictor of all-cause mortality [35,36]. To add a further complication, home blood pressure measurements may associate more closely with CVD than clinic blood pressure [37]. Although it is clear that pre- and post-hemodialysis blood pressure differ from interdialytic ambulatory blood pressure, which at times may be unsatisfactory, the former is more often used, as home and ambulatory blood pressure are often not feasible [38,39].

Overall, studies on antihypertensive agents in maintenance hemodialysis patients have been limited, and evidence available to guide practitioners is poor [39]. A 2010 recommendation from a KDIGO controversies conference stated that RAAS inhibitors, beta-blockers, and calcium channel blockers should all be strongly considered in this population, despite the lack of RCTs [39]. However, the very recently halted HDPAL study [27] (discussed above and in Table 1) suggests that beta-blockers may be superior to ACEI in preventing cardiovascular morbidity and all-cause hospitalization in this population of maintenance hemodialysis patients

with LVH and hypertension. An ongoing Italian prospective open-label RCT called Angiotensin-Converting Enzyme Inhibitors in Hemodialysis (ARCADIA – ClinicalTrials.gov identifier NCT00985322), which is comparing 2 years of treatment with an ACEI to non-RAAS inhibitor therapy on a composite endpoint of cardiovascular death and non-fatal myocardial infarction and stroke in chronic hemodialysis patients with LVH and hypertension, will provide a more definitive answer.

Factors that complicate blood pressure control in maintenance hemodialysis patients include the roles of fluid status and sodium balance. ESRD is characterized by a positive sodium balance and increased extracellular fluid volume, both of which contribute to hypertension. Thus, normalizing fluid and sodium balance is key in controlling blood pressure and reducing cardiovascular risk [39,40]. Other unique considerations in selecting antihypertensive agents in this population include timing (due to clearance with hemodialysis), impaired kidney excretion of drugs, and increased propensity to side effects [39,41]. KDIGO recommends considering individual patient circumstances, including CVD history, occurrence of interdialytic hypotension, and vascular access thrombosis, in the treatment of hypertension of maintenance dialysis patients [39].

Anemia

In addition to hypertension, the frequency of anemia increases with CKD progression, affecting nearly all chronic hemodialysis patients [42]. The major cause of anemia is insufficient production of erythropoietin by the kidney [43]. Maintenance hemodialysis patients also have increased iron losses, resulting from impaired absorption, increased bleeding, frequent phlebotomy, and blood trapping by the hemodialysis apparatus [42]. KDIGO recommends testing for anemia in non-anemic ESRD patients when clinically indicated and every 3 months and diagnosing anemia in adults and children more than 15 years of age when the hemoglobin concentration is less than 13.0 g/dL in males and less than 12.0 g/dL in females [44]. KDIGO also recommends that treatment options, which include erythropoiesis-stimulating agents (ESAs) and intravenous iron as well as target hemoglobin levels, balance the potential benefits and risk of harm to the patient.

The goal of intravenous iron is to ensure adequate stores for erythropoiesis, correct iron deficiency, and prevent it from occurring if ESA is also used [44]. KDIGO recommends a trial of intravenous iron for adults on maintenance hemodialysis with anemia if serum transferrin saturation is less than 30%, ferritin is less than 500 ng/mL, and an increase in hemoglobin or a decrease in ESA dose or

both are desired, with subsequent iron therapy guided by clinical response [44]. Furthermore, KDIGO recommends that all correctable causes of anemia (e.g. iron deficiency and inflammation [45]) be addressed prior to initiating ESA therapy. The overall recommendation is that ESA be used to avoid hemoglobin levels falling to less than 9.0 g/dL, with an initiation when hemoglobin level is 9 to 10 g/dL, and that in general therapy not be used to maintain hemoglobin of greater than 11.5 g/dL or to intentionally increase hemoglobin to greater than 13 g/dL. Individual considerations need to be made regarding the frequency, dose, and type of ESA. Hemoglobin levels should continue to be tested when clinically indicated and at least monthly.

These recommendations have arisen from controversial and (by comparison) conflicting epidemiological and randomized controlled study data. Epidemiological data supported an inverse association of hemoglobin with mortality [46,47] and other adverse outcomes such as cardiovascular events [48] up to the normal range. However, correction of anemia has had opposing results in RCTs. The earliest trial was the Normal Hematocrit Study (Table 1), which compared partial (to a hematocrit of 31%) and full (to a hematocrit of 40%) correction of anemia with ESA (epoetin-alfa) in 1233 prevalent hemodialysis patients with symptomatic heart failure or ischemic heart disease on the composite primary outcome of time to death or first non-fatal myocardial infarction [2]. In contrast to the epidemiological data, full correction of anemia tended to increase cardiovascular events (risk ratio 1.3, 95% CI 0.9 to 1.9), and the trial was halted early.

Two subsequent RCTs, although performed in non-dialysis-dependent CKD patients, found similar results of increased risk (of cardiovascular events [49] and initiation of dialysis—with no change eGFR rate of fall—[50]) with ESA to correct anemia to a higher as opposed to a lower hemoglobin target. In contrast, the most recent and largest (n = 4038) study to date—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)—found no difference in the two primary endpoints of (1) a composite of death and cardiovascular events and (2) composite of death and progression to ESRD in patients with stage 3 to 4 CKD and type 2 diabetes mellitus treated with ESA (darbepoetin-alfa) to achieve a target level of hemoglobin of 13 g/dL or placebo (with rescue if the hemoglobin level is less than 9 g/dL) [51]. However, the risk of stroke and venous thrombo-embolic events was increased in the treated group. Of note, an additional study in incident hemodialysis patients without symptomatic heart disease found no change in the primary endpoint of left ventricular mass index with full as

opposed to partial correction of hemoglobin with ESA (epoetin-alfa) [52]. Overall, the randomized controlled study data are inconsistent with the epidemiological data, thus influencing KDIGO's more conservative recommendations in the treatment of anemia in CKD and ESRD. These differences in results may be partially explained by the fact that the epidemiological data included patients with more severe anemia than the RCTs, or perhaps by the fact that patients requiring the highest dose of ESA also have higher systemic inflammation [53].

Mineral metabolism

With declining kidney function, there are progressive alterations in mineral metabolism, including changes in levels of calcium, phosphorus, and parathyroid hormone (PTH), which associate with increased risk of mortality [54,55]. The most comprehensive evidence of this occurrence in maintenance hemodialysis patients is from the international Dialysis Outcomes and Practice Pattern Study (DOPPS), which collected data on 17,236 patients in the US, Europe, and Japan from 1996 to 2001 [56]. The majority of patients fell outside of the recommended range for calcium, phosphorus, and intact PTH (iPTH), and higher levels of all three metabolites were significantly associated with increased risk of all-cause and cardiovascular mortality.

In DOPPS, 50% of maintenance hemodialysis patients had albumin-corrected calcium above and 9% below the recommended guideline range [56]. Additional observational studies have also supported an increased relative risk of mortality with hypercalcemia [57,58]. KDIGO recommends checking serum calcium levels every 1 to 3 months in maintenance dialysis patients and maintaining serum calcium levels within normal limits [54]. In the presence of hypercalcemia, it is recommended to limit use of calcium-based phosphate binders, 1,25 dihydroxyvitamin D [$1,25(\text{OH})_2\text{D}$ or calcitriol], and 1,25(OH)₂D analogs [54]. Finally, KDIGO suggests using a dialysate calcium concentration of between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L) [54].

Increased serum phosphorus level, even in the normal range, is consistently and independently associated with increased risk of cardiovascular events and mortality in maintenance hemodialysis patients [59-62]. KDIGO recommends checking serum phosphorus levels every 3 months in these patients and treating hyperphosphatemia toward the normal range (2.5 to 4.5 mg/dL) [54]. K/DOQI recommends treating hyperphosphatemia to a range of 2.5 to 5.5 mg/dL [63]. Options for the treatment of hyperphosphatemia include calcium-based phosphate binders and non-calcium binders (e.g. sevelamer hydrochloride (HCl), sevelamer carbonate, and lanthanum

carbonate) as well as dietary phosphate restriction [54]. KDIGO also suggests increasing dialytic phosphate removal in the treatment of persistent hyperphosphatemia [54].

Observational data support that treatment with a phosphate binder of any type provides a survival advantage in maintenance hemodialysis patients [64] and that sevelamer may reduce risk of mortality more effectively than calcium-based phosphate binders [65]. RCTs support that sevelamer may slow vascular calcification [59,66,67], but results are not consistent across all studies [68,69]. However, in the largest ($n = 2013$) RCT to date (Dialysis Clinical Outcomes Revisited, or DCOR), there was no difference in all-cause mortality in maintenance hemodialysis patients treated with sevelamer HCl as opposed to a calcium-based phosphate binder [70]. This is in contrast with a smaller ($n = 127$) study of incident hemodialysis patients which found an increased risk of mortality in the calcium-based binder group compared with the sevelamer HCl-treated group [59], and a recent meta-analysis that found a decreased risk of all-cause mortality in patients with CKD treated with non-calcium-based phosphate binders as opposed to calcium-based phosphate binders [71].

Finally, increased iPTH levels are also associated with increased cardiovascular events and mortality in maintenance hemodialysis patients, with an inflection point of around 400 to 600 pg/mL [55]. KDIGO recommends a target of two to nine times the upper limit of normal (i.e. 130 to 585 pg/mL) [54], and K/DOQI recommends a target of 150 to 300 pg/mL [63]. Treatment options include vitamin D [$1,25(\text{OH})_2\text{D}$ and $1,25(\text{OH})_2\text{D}$ analogs] and type II calcimimetics, which decrease PTH release by “mimicking” an increase in intracellular calcium through a conformation change in the calcium-sensing receptor [54]. Cinacalcet is the only type II calcimimetic available for clinical use and is approved by the US Food and Drug Administration to treat secondary hyperparathyroidism in dialysis patients. Observational data have shown that $1,25(\text{OH})_2\text{D}$ analogs increase survival, but this is likely confounded by indication [58,72,73] and is not a consistent finding [74,75]. Observational data have also shown no further benefit of cinacalcet use in maintenance hemodialysis patients compared with $1,25(\text{OH})_2\text{D}$ analogs [76].

In an RCT of maintenance hemodialysis patients with coronary calcification, treatment with cinacalcet plus low-dose $1,25(\text{OH})_2\text{D}$ or an analog lowered the rate and extent of calcification progression [77]. However, the best evidence to date on the efficacy of treatment of secondary hyperparathyroidism for reducing risk of cardiovascular events or mortality in maintenance hemodialysis patients

is from the EVOLVE study [7]. As discussed previously (see above and Table 1), in the unadjusted, intent-to-treat analysis, there was no reduction in primary composite endpoint with treatment with cinacalcet. Several editorials as well as letters to the editor regarding potential considerations in the interpretation of these results have been published [78–80].

Inflammation

An important future direction of RCTs to reduce cardiovascular events, mortality, or both is targeting systemic inflammation in chronic hemodialysis patients. Although no clear definition of inflammation is established in this population, levels of greater than 5 to 10 mg/L of the acute-phase reactant C-reactive protein (CRP) have been proposed by National Kidney Foundation K/DOQI guidelines as a marker of inflammation [31]. When CRP is used as a marker, chronic systemic inflammation is highly prevalent in hemodialysis patients and is an independent predictor of all-cause and cardiovascular mortality [81,82]. CRP expression is driven mainly by interleukin-1 (IL-1), a pleiotropic pro-inflammatory cytokine elevated in chronic hemodialysis patients [83,84] and also predictive of overall and cardiovascular mortality [85]. The pro-inflammatory cytokine IL-6 is also a strong predictor of cardiovascular mortality in this population [86,87].

Whether inhibiting inflammatory pathways in chronic hemodialysis patients may reduce cardiovascular and all-cause mortality is currently untested. Early work in this area supports that this may be an important future direction for randomized clinical trials. It was recently demonstrated that blockade of the pleiotropic pro-inflammatory cytokine IL-1 β is efficacious in reducing circulating inflammatory markers in maintenance hemodialysis patients [88]. Determining whether reducing inflammation via inhibition of IL-1 β or other pathways reduces cardiovascular mortality is a novel and important future direction for RCTs.

Conclusions

Morbidity and mortality in maintenance hemodialysis patients are extremely high, and management of care is complex. Among the issues important to care as related cardiovascular outcomes are the cardiovascular disease burden, blood pressure control, anemia, abnormalities in mineral metabolism, and inflammation. These topics are complicated by sometimes conflicting observational and RCT data. The RCTs to date have been largely unsuccessful in reducing primary outcomes of CVD events, mortality, or both. It is possible that, although RCTs to date have been ineffective, newer therapies targeting these factors may be more successful, such as

targeting inflammation to treat anemia and using fibroblast growth factor-23 inhibitors to treat abnormalities in mineral metabolism. In addition, certain risk factors, including the efficacy of phosphate lowering and adequate blood pressure control to reduce mortality, still have not been well tested in RCTs to date. Finally, new directions are key for future RCTs, with reductions in inflammation being one example of a very attractive target. As treatment options for reducing CVD events, mortality, or both in maintenance hemodialysis are currently limited, future RCTs related to each of these points should be considered, with the goal of ultimately improving hard outcomes.

Abbreviations

ACEI, angiotensin-converting enzyme inhibitor; CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; CVD, cardiovascular disease; DOPPS, Dialysis Outcomes and Practice Pattern Study; eGFR, estimated glomerular filtration rate; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; EVOLVE, Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events; HCl, hydrochloride; HDPAL, Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril; IL, interleukin; iPTH, intact parathyroid hormone; KDIGO, Kidney Disease: Improving Global Outcomes; K/DOQI, Kidney Disease Outcomes Quality Initiative; LVH, left ventricular hypertrophy; PTH, parathyroid hormone; RAAS, renin angiotensin aldosterone system; RCT, randomized controlled trial.

Disclosures

The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.

Acknowledgments

This work was supported by the American Heart Association (12POST11920023).

References

1. U.S. Renal Data System: **USRDS 2013 Annual Data Report**. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
2. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: **The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin**. *N Engl J Med* 1998, **339**:584-90.



3. Eknayan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS,

Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: **Effect of dialysis dose and membrane flux in maintenance hemodialysis**. *N Engl J Med* 2002, **347**:2010-9.

4. Wanner C, Krane V, März W, Olschewski M, Mann, Johannes FE, Ruf G, Ritz E: **Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis**. *N Engl J Med* 2005, **353**:238-48.
5. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM: **Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial**. *JAMA* 2007, **298**:1163-70.



6. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae D, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima, José J, Lins R, Mayer G, McMahon AW, Parving H, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F: **Rosuvastatin and cardiovascular events in patients undergoing hemodialysis**. *N Engl J Med* 2009, **360**:1395-407.



7. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix, T Christian H, Moe SM, Trotman M, Wheeler DC, Parfrey PS: **Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis**. *N Engl J Med* 2012, **367**:2482-94.



8. U.S. Renal Data System: **USRDS 2012 Annual Data Report**. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
9. Selby NM, McIntyre CW: **The acute cardiac effects of dialysis**. *Semin Dial* 2007, **20**:220-8.
10. Kahn MR, Robbins MJ, Kim MC, Fuster V: **Management of cardiovascular disease in patients with kidney disease**. *Nat Rev Cardiol* 2013, **10**:261-73.
11. Kendrick J, Chonchol MB: **Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease**. *Nat Clin Pract Nephrol* 2008, **4**:672-81.
12. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknayan G: **National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification**. *Ann Intern Med* 2003, **139**:137-47.
13. Stack AG, Bloembergen WE: **Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study**. *J Am Soc Nephrol* 2001, **12**:1516-23.



14. Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR: **Chronic kidney disease is associated with angiographic coronary artery disease**. *Am J Nephrol* 2008, **28**:354-60.
15. Nakano T, Ninomiya T, Sumiyoshi S, Fujii H, Doi Y, Hirakata H, Tsuruya K, Iida M, Kiyohara Y, Sueishi K: **Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study**. *Am J Kidney Dis* 2010, **55**:21-30.
16. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, Wolfe M, Neschis D, Milner R, Scoll B, Cusack A, Mohler ER: **Bone formation in carotid plaques: a clinicopathological study**. *Stroke* 2002, **33**:1214-9.
17. Hruska KA, Saab G, Mathew S, Lund R: **Renal osteodystrophy, phosphate homeostasis, and vascular calcification**. *Semin Dial* 2007, **20**:309-15.
18. Jablonski KL, Chonchol M: **Vascular calcification in end-stage renal disease**. *Hemodial Int* 2013, **17**(Suppl 1):S17-21.

19. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: **Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.** *Hypertension* 2001, **38**:938-42.
- F1000Prime RECOMMENDED**
20. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: **Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.** *Nephrol Dial Transplant* 2003, **18**:1731-40.
- F1000Prime RECOMMENDED**
21. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: **Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.** *Kidney Int* 1995, **47**:186-92.
22. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt K, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: **Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).** *Kidney Int* 2011, **80**:572-86.
23. Remppis A, Ritz E: **Cardiac problems in the dialysis patient: beyond coronary disease.** *Semin Dial* 2008, **21**:319-25.
24. Green D, Roberts PR, New DI, Kalra PA: **Sudden cardiac death in hemodialysis patients: an in-depth review.** *Am J Kidney Dis* 2011, **57**:921-9.
25. Furgeson SB, Chonchol M: **Beta-blockade in chronic dialysis patients.** *Semin Dial* 2008, **21**:43-8.
26. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairitichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, Zeeuw D de, Grönhagen-Riska C, Dasgupta T et al.: **The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.** *Lancet* 2011, **377**:2181-92.
- F1000Prime RECOMMENDED**
27. Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG: **Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.** *Nephrol Dial Transplant* 2014, **29**:672-81.
- F1000Prime RECOMMENDED**
28. Agarwal R, Nissenson AR, Battle D, Coyne DW, Trout JR, Warnock DG: **Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.** *Am J Med* 2003, **115**:291-7.
29. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E: **2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).** *JAMA* 2014, **311**:507-20.
30. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group: **KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.** *Kidney Int Suppl* 2012, **2**:337-414.
31. **K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.** *Am J Kidney Dis* 2005, **45**:S1-153.
32. Li Z, Lacson E, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin NW: **The epidemiology of systolic blood pressure and death risk in hemodialysis patients.** *Am J Kidney Dis* 2006, **48**:606-15.
33. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: **“U” curve association of blood pressure and mortality in hemodialysis patients.** *Medical Directors of Dialysis Clinic, Inc. Kidney Int* 1998, **54**:561-9.
34. Stidley CA, Hunt WC, Tentori F, Schmidt D, Rohrscheib M, Paine S, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: **Changing relationship of blood pressure with mortality over time among hemodialysis patients.** *J Am Soc Nephrol* 2006, **17**:513-20.
35. Tozawa M, Iseki K, Yoshi S, Fukiyama K: **Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease.** *Nephrol Dial Transplant* 1999, **14**:1976-81.
- F1000Prime RECOMMENDED**
36. Brunelli SM, Thadhani RI, Lynch KE, Ankers ED, Joffe MM, Boston R, Chang Y, Feldman HI: **Association between long-term blood pressure variability and mortality among incident hemodialysis patients.** *Am J Kidney Dis* 2008, **52**:1716-26.
- F1000Prime RECOMMENDED**
37. Alborzi P, Patel N, Agarwal R: **Home blood pressures are of greater prognostic value than hemodialysis unit recordings.** *Clin J Am Soc Nephrol* 2007, **2**:1228-34.
- F1000Prime RECOMMENDED**
38. Agarwal R, Peixoto AJ, Santos, Sergio FF, Zoccali C: **Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure.** *Clin J Am Soc Nephrol* 2006, **1**:389-98.
39. Levin NW, Kotanko P, Eckardt K, Kasiske BL, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM: **Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference.** *Kidney Int* 2010, **77**:273-84.
40. Guyton AC, Coleman TG, Granger HJ: **Circulation: overall regulation.** *Annu Rev Physiol* 1972, **34**:13-46.
41. Sułowicz W, Radziszewski A: **Dialysis induced hypotension—a serious clinical problem in renal replacement therapy.** *Med Pregl* 2007, **60**(Suppl 2):14-20.
42. Babitt JL, Lin HY: **Mechanisms of anemia in CKD.** *J Am Soc Nephrol* 2012, **23**:1631-4.
43. **KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.** *Am J Kidney Dis* 2006, **47**:S11-145.
44. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: **KDIGO 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease.** *Kidney Int Suppl* 2013, **2**:281-355.
45. Smrzova J, Balla J, Bárány P: **Inflammation and resistance to erythropoiesis-stimulating agents—what do we know and what needs to be clarified?** *Nephrol Dial Transplant* 2005, **20**(Suppl 8):viii2-7.
46. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: **The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.** *Kidney Int* 2003, **63**:1908-14.
47. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: **Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.** *J Am Soc Nephrol* 2006, **17**:1181-91.
48. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: **The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease.** *Am J Kidney Dis* 1996, **28**:53-61.
49. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: **Correction of anemia with epoetin alfa in chronic kidney disease.** *N Engl J Med* 2006, **355**:2085-98.
- F1000Prime RECOMMENDED**
50. Drüeke TB, Locatelli F, Clyne N, Eckardt K, Macdougall IC, Tsakiris D, Burger H, Scherhag A: **Normalization of hemoglobin level in**

patients with chronic kidney disease and anemia. *N Engl J Med* 2006, **355**:2071-84.



51. Pfeffer MA, Burdman EA, Chen C, Cooper ME, Zeeuw D de, Eckardt K, Fezzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray, John JV, Parfrey P, Parving H, Remuzzi G, Singh AK, Solomon SD, Toto R: **A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.** *N Engl J Med* 2009, **361**:2019-32.
52. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: **Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.** *J Am Soc Nephrol* 2005, **16**:2180-9.
53. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: **Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.** *Kidney Int* 2008, **74**:791-8.
54. **KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).** *Kidney Int Suppl* 2009, **S1**-130.
55. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: **Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.** *J Am Soc Nephrol* 2004, **15**:2208-18.
56. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: **Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.** *Kidney Int* 2005, **67**:1179-87.
57. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Kawaguchi Y, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: **Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study.** *Hemodial Int* 2007, **11**:340-8.
58. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: **Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.** *Kidney Int* 2006, **70**:771-80.
59. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: **Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.** *Kidney Int* 2005, **68**:1815-24.
60. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: **Serum phosphate levels and mortality risk among people with chronic kidney disease.** *J Am Soc Nephrol* 2005, **16**:520-8.
61. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: **Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.** *Am J Kidney Dis* 1998, **31**:607-17.
62. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P: **Mild hyperphosphatemia and mortality in hemodialysis patients.** *Am J Kidney Dis* 2005, **46**:68-77.
63. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S: **KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).** *Am J Kidney Dis* 2010, **55**:773-99.
64. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M: **Phosphorus binders and survival on hemodialysis.** *J Am Soc Nephrol* 2009, **20**:388-96.
65. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: **Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.** *Kidney Int* 2007, **71**:438-41.
66. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: **The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.** *Kidney Int* 2007, **72**:1255-61.
67. Chertow GM, Burke SK, Raggi P: **Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.** *Kidney Int* 2002, **62**:245-52.
68. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M: **A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renigel Evaluation-2 (CARE-2) study.** *Am J Kidney Dis* 2008, **51**:952-65.
69. Barreto DV, Barreto, Fellype de Carvalho, de Carvalho, Aluizio Barbosa, Cuppari L, Draibe SA, Dalboni MA, Moyses, Rosa Maria Affonso, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani, Maria Eugénia Fernandes: **Phosphate binder impact on bone remodeling and coronary calcification—results from the BRiC study.** *Nephron Clin Pract* 2008, **110**:c273-83.
70. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: **Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.** *Kidney Int* 2007, **72**:1130-7.
71. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT: **Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.** *Lancet* 2013, **382**:1268-77.
72. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R: **Vitamin D levels and early mortality among incident hemodialysis patients.** *Kidney Int* 2007, **72**:1004-13.
73. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: **Mortality risk among hemodialysis patients receiving different vitamin D analogs.** *Kidney Int* 2006, **70**:1858-65.
74. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK: **The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study.** *Nephrol Dial Transplant* 2009, **24**:963-72.
75. St Peter, Wendy L, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ: **Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.** *Pharmacotherapy* 2009, **29**:154-64.
76. Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio Paparatti, Umberto, Mazzaferro S: **Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.** *Blood Purif* 2011, **32**:124-32.
77. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J: **The ADVANCE study: a randomized study to evaluate the**

effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. *Nephrol Dial Transplant* 2011, **26**:1327-39.



78. Goldsmith D, Covic A: **The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?** *Int J Clin Pract* 2014, **68**:286-9.
79. Perkovic V, Neal B: **Trials in kidney disease—time to EVOLVE.** *N Engl J Med* 2012, **367**:2541-2.
80. Tripepi G: **Cinacalcet for cardiovascular disease in patients undergoing dialysis.** *N Engl J Med* 2013, **368**:1843-4.
81. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: **Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.** *Kidney Int* 1999, **55**:648-58.
82. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: **C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.** *Am J Kidney Dis* 2000, **35**:469-76.
83. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: **Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients.** *Kidney Int* 1994, **45**:890-6.
84. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, Groote D de, Jungers P: **Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.** *J Immunol* 1995, **154**:882-92.
85. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: **Immunologic function and survival in hemodialysis patients.** *Kidney Int* 1998, **54**:236-44.
86. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: **Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.** *Am J Kidney Dis* 1998, **32**:107-14.
87. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: **Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.** *Am J Kidney Dis* 2006, **47**:139-48.
88. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA: **IL-1 β receptor antagonist reduces inflammation in hemodialysis patients.** *J Am Soc Nephrol* 2011, **22**:437-42.

